SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation firm engineering high-fidelity vaccines to guard humankind from the results of bacterial illnesses, introduced right now the closing of its beforehand introduced underwritten public providing of 12,695,312 shares of frequent inventory at a public providing worth of $64.00 per share and pre-funded warrants to buy 781,250 shares of frequent inventory at a public providing worth of $63.999 per underlying share. This consists of the train in full by the underwriters of their choice to buy as much as 1,757,812 extra shares of frequent inventory on the public providing worth per share, much less underwriting reductions and commissions. The mixture gross proceeds to Vaxcyte from this providing have been roughly $862.5 million, earlier than deducting underwriting reductions and commissions and different providing bills payable by Vaxcyte.
BofA Securities, Jefferies, Leerink Companions LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint book-running managers for the providing. BTIG and Needham & Firm acted as lead managers for the providing.
A shelf registration assertion regarding the provided securities was filed with the Securities and Trade Fee (SEC), and was mechanically efficient upon submitting on July 2, 2021. A last prospectus complement and accompanying prospectus regarding the providing has been filed with the SEC and is obtainable on the SEC’s web site, positioned at www.sec.gov. Copies of the ultimate prospectus complement and the accompanying prospectus regarding this providing could also be obtained from BofA Securities NC1-022-02-25, Consideration: Prospectus Division, 201 North Tryon Avenue, Charlotte, North Carolina 28255-0001 or by e mail at dg.prospectus_requests@bofa.com; Jefferies LLC, Consideration: Fairness Syndicate Division, 520 Madison Avenue, New York, New York 10022, by phone at 1-877-821-7388, or by e mail at Prospectus_Department@Jefferies.com; Leerink Companions LLC, Consideration: Syndicate Division, 53 State Avenue, fortieth Flooring, Boston, MA 02109, by e mail at syndicate@leerink.com or by cellphone at (800) 808-7525, ext. 6105; and Evercore Group L.L.C., Consideration: Fairness Capital Markets, 55 East 52nd Avenue, thirty fifth Flooring, New York, New York 10055, by phone at 1-888-474-0200 or by e mail at ecm.prospectus@evercore.com.
This press launch shall not represent a proposal to promote or a solicitation of a proposal to purchase these securities nor shall there be any sale of those securities in any state or jurisdiction during which such provide, solicitation or sale can be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.
About Vaxcyte
Vaxcyte is a vaccine innovation firm engineering high-fidelity vaccines to guard humankind from the results of bacterial illnesses. The Firm is creating broad-spectrum conjugate and novel protein vaccines to stop or deal with bacterial infectious illnesses. Vaxcyte’s lead candidate, VAX-24, is a Section 3-ready 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal illness. VAX-31, the Firm’s next-generation 31-valent PCV, is the broadest-spectrum PCV candidate within the clinic right now.
Vaxcyte is re-engineering the way in which extremely advanced vaccines are made via fashionable artificial strategies, together with superior chemistry and the XpressCF™ cell-free protein synthesis platform, solely licensed from Sutro Biopharma, Inc. In contrast to standard cell-based approaches, the Firm’s system for producing difficult-to-make proteins and antigens is meant to speed up its means to effectively create and ship high-fidelity vaccines with enhanced immunological advantages. Vaxcyte’s pipeline additionally consists of VAX-A1, a prophylactic vaccine candidate designed to stop Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to gradual or cease the development of periodontal illness; and VAX-GI, a vaccine program designed to stop Shigella. Vaxcyte is pushed to eradicate or deal with invasive bacterial infections, which have severe and expensive well being penalties when left unchecked.
Contacts:
Janet Graesser, Vice President, Company Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor Relations
Vaxcyte, Inc.
860-729-8902
buyers@vaxcyte.com
